JP7896880B2 - ヘテロアリール誘導体化合物およびその用途{Heteroaryl derivative compounds,and uses thereof} - Google Patents

ヘテロアリール誘導体化合物およびその用途{Heteroaryl derivative compounds,and uses thereof}

Info

Publication number
JP7896880B2
JP7896880B2 JP2022573567A JP2022573567A JP7896880B2 JP 7896880 B2 JP7896880 B2 JP 7896880B2 JP 2022573567 A JP2022573567 A JP 2022573567A JP 2022573567 A JP2022573567 A JP 2022573567A JP 7896880 B2 JP7896880 B2 JP 7896880B2
Authority
JP
Japan
Prior art keywords
pyrimidine
amine
phenyl
isoxazolidine
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022573567A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519626A5 (cg-RX-API-DMAC7.html
JP2024519626A (ja
Inventor
イ,ユンホ
ファン,ソンア
シム,インソプ
チョン,ヒョンホ
ド,ウミ
リュ,ヒソン
ソン,ジョンボム
キム,ナムドゥ
キム,ソンファン
チョン,ホンリョル
イ,ヨンイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voronoi Inc
Original Assignee
Voronoi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voronoi Inc filed Critical Voronoi Inc
Publication of JP2024519626A publication Critical patent/JP2024519626A/ja
Publication of JP2024519626A5 publication Critical patent/JP2024519626A5/ja
Application granted granted Critical
Publication of JP7896880B2 publication Critical patent/JP7896880B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2022573567A 2021-05-17 2022-05-16 ヘテロアリール誘導体化合物およびその用途{Heteroaryl derivative compounds,and uses thereof} Active JP7896880B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20210063733 2021-05-17
KR10-2021-0063733 2021-05-17
PCT/KR2022/006994 WO2022245085A1 (ko) 2021-05-17 2022-05-16 헤테로아릴 유도체 화합물 및 이의 용도

Publications (3)

Publication Number Publication Date
JP2024519626A JP2024519626A (ja) 2024-05-21
JP2024519626A5 JP2024519626A5 (cg-RX-API-DMAC7.html) 2025-03-25
JP7896880B2 true JP7896880B2 (ja) 2026-07-29

Family

ID=84141801

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573567A Active JP7896880B2 (ja) 2021-05-17 2022-05-16 ヘテロアリール誘導体化合物およびその用途{Heteroaryl derivative compounds,and uses thereof}

Country Status (12)

Country Link
US (3) US12037330B2 (cg-RX-API-DMAC7.html)
EP (1) EP4342895A4 (cg-RX-API-DMAC7.html)
JP (1) JP7896880B2 (cg-RX-API-DMAC7.html)
KR (2) KR102607051B1 (cg-RX-API-DMAC7.html)
CN (1) CN115667251A (cg-RX-API-DMAC7.html)
AU (1) AU2022271388A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024068A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180295A1 (cg-RX-API-DMAC7.html)
IL (1) IL298474A (cg-RX-API-DMAC7.html)
MX (1) MX2022014887A (cg-RX-API-DMAC7.html)
TW (1) TWI869674B (cg-RX-API-DMAC7.html)
WO (1) WO2022245085A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN115667251A (zh) * 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501183A (ja) 2002-07-09 2006-01-12 ノバルティス アクチエンゲゼルシャフト フェニル−[4−(3−フェニル−1h−ピラゾール−4−イル)−ピリミジン−2−イル]−アミン誘導体
WO2009008371A1 (ja) 2007-07-06 2009-01-15 Astellas Pharma Inc. ジ(アリールアミノ)アリール化合物
JP2017530999A (ja) 2014-10-13 2017-10-19 ユハン コーポレーションYuhan Corporation Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物
JP2017532326A (ja) 2014-10-11 2017-11-02 シャンハイ ハンソウ バイメディカル カンパニー リミテッド Egfr阻害薬、およびそれらの製造および応用
JP2020526499A (ja) 2017-07-05 2020-08-31 シーエス ファーマテック リミテッド Egfrチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤
WO2020190119A1 (ko) 2019-03-19 2020-09-24 주식회사 보로노이 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
WO2020235902A1 (ko) 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
JP2023541992A (ja) 2020-09-18 2023-10-04 ボロノイバイオ インコーポレイテッド ヘテロアリール誘導体、そのヘテロアリール誘導体の調製方法、及びそのヘテロアリール誘導体を活性成分として含む医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161662A0 (en) 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
US11440899B2 (en) 2017-10-17 2022-09-13 Merck Patent Gmbh Pyrimidine TBK/IKKe inhibitor compounds and uses thereof
KR20210032093A (ko) 2019-09-16 2021-03-24 제이투에이치바이오텍 (주) Egfr 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도
KR20220085735A (ko) 2020-12-14 2022-06-22 보로노이바이오 주식회사 아이소옥사졸리딘 유도체 화합물 및 이의 용도
US20240262815A1 (en) 2021-05-07 2024-08-08 Voronoi Inc. Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
CN115667251A (zh) * 2021-05-17 2023-01-31 株式会社沃若诺伊生物 杂芳基衍生物化合物、及其用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501183A (ja) 2002-07-09 2006-01-12 ノバルティス アクチエンゲゼルシャフト フェニル−[4−(3−フェニル−1h−ピラゾール−4−イル)−ピリミジン−2−イル]−アミン誘導体
WO2009008371A1 (ja) 2007-07-06 2009-01-15 Astellas Pharma Inc. ジ(アリールアミノ)アリール化合物
JP2017532326A (ja) 2014-10-11 2017-11-02 シャンハイ ハンソウ バイメディカル カンパニー リミテッド Egfr阻害薬、およびそれらの製造および応用
JP2017530999A (ja) 2014-10-13 2017-10-19 ユハン コーポレーションYuhan Corporation Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物
JP2020526499A (ja) 2017-07-05 2020-08-31 シーエス ファーマテック リミテッド Egfrチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤
WO2020190119A1 (ko) 2019-03-19 2020-09-24 주식회사 보로노이 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물
WO2020235902A1 (ko) 2019-05-17 2020-11-26 주식회사 보로노이 헤테로고리 융합 피리미딘 유도체 및 이의 용도
JP2023541992A (ja) 2020-09-18 2023-10-04 ボロノイバイオ インコーポレイテッド ヘテロアリール誘導体、そのヘテロアリール誘導体の調製方法、及びそのヘテロアリール誘導体を活性成分として含む医薬組成物

Also Published As

Publication number Publication date
US20240317730A1 (en) 2024-09-26
US12534457B2 (en) 2026-01-27
TWI869674B (zh) 2025-01-11
TW202310845A (zh) 2023-03-16
US20240166640A1 (en) 2024-05-23
IL298474A (en) 2023-01-01
CN115667251A (zh) 2023-01-31
US20240025888A1 (en) 2024-01-25
AU2022271388A1 (en) 2022-12-01
US12037330B2 (en) 2024-07-16
KR20220156453A (ko) 2022-11-25
EP4342895A4 (en) 2025-09-10
CA3180295A1 (en) 2022-11-24
BR112022024068A2 (pt) 2023-12-05
EP4342895A1 (en) 2024-03-27
KR20230163335A (ko) 2023-11-30
KR102607051B1 (ko) 2023-11-30
US12528799B2 (en) 2026-01-20
WO2022245085A1 (ko) 2022-11-24
JP2024519626A (ja) 2024-05-21
MX2022014887A (es) 2023-01-11

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230829

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251223

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260609

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260709

R150 Certificate of patent or registration of utility model

Ref document number: 7896880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150